Most patients survive acute myocardial infarction (MI). Yet this encouraging development
has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …

Aims Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart
failure and for death in patients with symptomatic heart failure. However, trials investigating …

Background In patients with acute myocardial infarction (MI), therapies that could further
reduce the risk of adverse cardiovascular and metabolic outcomes are needed. Methods In …

Background Patients with acute myocardial infarction (MI) are at risk for developing heart
failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose …

Abstract Purpose of Review Ischemic cardiomyopathy refers to systolic left ventricular
dysfunction in the setting of obstructive coronary artery disease and represents the most …

Abstract Sodium glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes
in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure …

Diagnostic and therapeutic advances during the past decades have substantially improved
health outcomes for patients with acute coronary syndrome. Both age-related physiological …

Myocardial infarction (MI) is the leading cause of death and morbidity worldwide, with an
incidence relatively high in developed countries and rapidly growing in developing …